35 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
or the capital markets. However, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all … and there is no assurance that we will enter into an ELOC or, if we do enter into such an ELOC, that the terms thereof will be consistent with or as favorable
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
or the capital markets. However, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all … and there is no assurance that we will enter into an ELOC or, if we do enter into such an ELOC, that the terms thereof will be consistent with or as favorable
10-Q
2024 Q1
EX-31.1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
expenses, and the Company may need to raise additional funds through either strategic partnerships or the capital markets. However, there is no assurance … ELOC has not been, and may never be, finalized and executed and there is no assurance that we will enter into an ELOC or, if we do enter
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations … controls and procedures or our internal control over financial reporting;
There is no assurance that we will enter into our proposed Equity Line
424B3
l1pz35a
16 Apr 24
Prospectus supplement
5:45pm
10-K
tzvz7
16 Apr 24
Annual report
4:48pm
10-K
EX-31.1
12g8hm50nbl809jzgp
16 Apr 24
Annual report
4:48pm
10-K
EX-31.2
5pb9v7r9odomhsrj9i2
16 Apr 24
Annual report
4:48pm
S-8
EX-5.1
hkibw2prwohuc h95b
12 Apr 24
Registration of securities for employees
7:22pm
8-K
EX-1.1
1sa56qw99d1zjj1
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
9e1 zurp7btl
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
80r2bg3qrdhrb tirs
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
hnyzb 4qv4x
20 Feb 24
Prospectus supplement with pricing info
5:28pm
CORRESP
tv3p4hh9xt3c0y
30 Jan 24
Correspondence with SEC
12:00am